Does Rallies show Form 4 insider transactions for RMD?

Yes. Rallies tracks RMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RMD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RMD. It does not provide personalized investment advice.

RMD (ResMed Inc.) Stock Analysis - Insider Trades

ResMed Inc. (RMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RMD trades at $210.64 with a market cap of $29.61B and a P/E ratio of 20.24. RMD moved +1.11% today. Year to date, RMD is -14.47%; over the trailing twelve months it is -15.43%. Its 52-week range spans $198.61 to $293.81. Analyst consensus is buy with an average price target of $264.56. Rallies surfaces RMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RMD stock inside the company?

Recent RMD insider activity includes Farrell Michael J. sold 4.99K, Farrell Michael J. sold 4.99K, Sandercock Brett sold 1.00K, FARRELL PETER C sold 2.00K, and Farrell Michael J. sold 4.99K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RMD Key Metrics

Key financial metrics for RMD
Metric	Value
Price	$210.64
Market Cap	$29.61B
P/E Ratio	20.24
EPS	$10.41
Dividend Yield	0.60%
52-Week High	$293.81
52-Week Low	$198.61
Volume	146
Avg Volume	0
Revenue (TTM)	$5.54B
Net Income	$1.52B
Gross Margin	61.59%

Recent RMD Insider Trades

Farrell Michael J. sold 4.99K (~$1.04M) on May 7, 2026.
Farrell Michael J. sold 4.99K (~$1.13M) on Apr 7, 2026.
Sandercock Brett sold 1.00K (~$224.31K) on Apr 1, 2026.
FARRELL PETER C sold 2.00K (~$450.00K) on Apr 1, 2026.
Farrell Michael J. sold 4.99K (~$1.25M) on Mar 9, 2026.

Latest RMD News

ResMed slides after Q3 beat as investors eye costs and post-earnings positioning — May 1, 2026
ResMed’s AirTouch N30i Mask Gains 6% Compliance Lift, Noctrix Acquisition Raises Margins — May 1, 2026
ResMed slides 3% after Q3 earnings: beat on sales, but costs and outlook worry — Apr 30, 2026
ResMed CFO Brett Sandercock Retires After 20 Years; Aaron Bloomer Appointed — Apr 30, 2026
ResMed’s $255 Price Target Signals 11.7% Upside as Insiders Sell $1.5M Shares — Apr 13, 2026

RMD Analyst Consensus

13 analysts cover RMD: 0 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.56.

Common questions about RMD

Who is trading RMD stock inside the company?: Recent RMD insider activity includes Farrell Michael J. sold 4.99K, Farrell Michael J. sold 4.99K, Sandercock Brett sold 1.00K, FARRELL PETER C sold 2.00K, and Farrell Michael J. sold 4.99K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RMD?: Yes. Rallies tracks RMD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RMD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RMD. It does not provide personalized investment advice.